The Effect of CoQ10 Administration on Hemodialysis Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00307996
Recruitment Status : Completed
First Posted : March 28, 2006
Last Update Posted : March 28, 2006
Information provided by:
University of Shizuoka

Brief Summary:
The purpose of this study is to examine whether CoQ10 administration is effective as an antioxidant in hemodialysis patients.

Condition or disease Intervention/treatment Phase
Chronic Renal Failure Hemodialysis Drug: Coenzyme Q10 (drug) Phase 4

Detailed Description:
Oxidative stress has been recognized as a potential risk factor for such complications as atherosclerosis in hemodialysis patients. This study investigates whether CoQ10 administration is effective for protecting oxidative stress in hemodialysis patients. The subjects were recruited from day-time hemodialysis patients in Iwata City Hospital. 100 mg CoQ10 was administered every HD for 6 months. Several oxidative and antioxidative markers were measured in plasma at pre, 1, 3, 6 months and after washout.

Study Type : Interventional  (Clinical Trial)
Enrollment : 40 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Effect of CoQ10 Administration on the Oxidative and Antioxidative Markers in Hemodialysis Patients
Study Start Date : March 2004
Study Completion Date : December 2004

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dialysis

Primary Outcome Measures :
  1. Oxidative protein concentration at 6 month
  2. Antioxidant capacity at 6 month

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   up to 85 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • hemodialysis for at least 6 months

Exclusion Criteria:

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00307996

Iwata City Hospital
Iwata, Shizuoka, Japan, 438-8550
Sponsors and Collaborators
University of Shizuoka
Study Chair: Hiromichi Kumagai, MD University of Shizuoka Identifier: NCT00307996     History of Changes
Other Study ID Numbers: CT2006001
First Posted: March 28, 2006    Key Record Dates
Last Update Posted: March 28, 2006
Last Verified: March 2006

Keywords provided by University of Shizuoka:
oxidative marker

Additional relevant MeSH terms:
Renal Insufficiency
Kidney Failure, Chronic
Kidney Diseases
Urologic Diseases
Renal Insufficiency, Chronic
Coenzyme Q10
Growth Substances
Physiological Effects of Drugs